Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Compared with other systemic agents for treating atopic dermatitis, dupilumab is associated with an increased risk for ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

“Atopic dermatitis, a chronic disease with underlying ... Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that ...

This study reveals that dupilumab is associated with a modestly increased risk of developing psoriasis, highlighting the ...

Paris: Sanofi has announced that results from the DISCOVER phase 4, single-arm, open-label study assessing Dupixent ...

Atopic dermatitis manifests differently in patients with darker skin color, according to the companies, including subtler ...

PORTLAND, OR, UNITED STATES, June 18, 2025 /EINPresswire.com/ -- The global atopic dermatitis market is witnessing unprecedented growth, projected to expand from $5.3 billion in 2021 to $22.6 billion ...